Rivaroxaban News and Research

RSS
Rivaroxaban ruled out for extended thromboprophylaxis

Rivaroxaban ruled out for extended thromboprophylaxis

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

Patients with AF experience more GI bleeding with rivaroxaban use

Patients with AF experience more GI bleeding with rivaroxaban use

Janssen introduces new online scientific resource for U.S. healthcare professionals

Janssen introduces new online scientific resource for U.S. healthcare professionals

Arthroplasty wound complications linked to oral anticoagulant use

Arthroplasty wound complications linked to oral anticoagulant use

Rivaroxaban effective in children

Rivaroxaban effective in children

Rivaroxaban effective in children

Rivaroxaban effective in children

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

‘Risky’ view of thrombolysis in subtherapeutic warfarin patients disputed

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen receives FDA complete response letter for XARELTO sNDA

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban safer, effective than standard therapy in treating PE

Rivaroxaban safer, effective than standard therapy in treating PE

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA assigns Priority Review designation to JRD's XARELTO sNDA

FDA assigns Priority Review designation to JRD's XARELTO sNDA